Literature DB >> 31025143

Effect of tocilizumab, an interleukin-6 inhibitor, on early stage streptozotocin-induced diabetic nephropathy in rats.

Aly M Abdelrahman1, Yousuf Al Suleimani2, Asem Shalaby3,4, Mohammed Ashique2, Priyadarsini Manoj2, Badreldin H Ali2.   

Abstract

The aim of this study was to examine the effect of tocilizumab, an interleukin-6 (IL-6) inhibitor on streptozotocin-induced diabetic nephropathy. Male Sprague-Dawley rats (n = 36) were distributed into six groups and treated for 4 weeks. Groups 1, 3, 5 received either saline, tocilizumab (2 mg/kg), or tocilizumab (8 mg/kg) injection intraperitoneally (i.p.), every 2 weeks, respectively. Groups 2, 4, 6 were rendered diabetic by a single i.p. injection of streptozotocin (65 mg/kg) and were treated as in groups 1, 3, 5, respectively. Biochemical parameters were measured in plasma, urine, and kidneys. In the untreated diabetic group, there was a significant decrease in body weight, polyuria, and increased kidney weight. There was increased urinary albumin/creatinine ratio (UACR) and N-acetyl-β-D-glucosaminidase (NAG)/creatinine ratio (UNCR). Streptozotocin also induced a significant increase in creatinine clearance. In addition, diabetes was associated with increased oxidative stress [reduced renal glutathione reductase (GR), superoxide dismutase (SOD), catalase activities, and increased malondialdhyde (MDA)] and increased plasma tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and nitric oxide (NO) concentrations. Kidneys from streptozotocin-treated rats showed marked vacuolation of the proximal tubular epithelium with focal tubular necrosis and the glomeruli showing increase in mesangial cells. Tocilizumab significantly mitigated the increase in UACR and UNCR, renal MDA, plasma TNF-α, IL-6 and NO levels, and the decrease in renal SOD and catalase activities in diabetic rats. Tocilizumab did not significantly improve creatinine clearance; however, it attenuated the histopathological changes induced by streptozotocin. This study shows that tocilizumab was able to ameliorate some of the changes seen in streptozotocin-induced early diabetic nephropathy in rats. This is mainly due to its anti-inflammatory and antioxidative effects.

Entities:  

Keywords:  Diabetes; Interleukin-6 inhibitor; Nephropathy; Streptozotocin; Tocilizumab

Year:  2019        PMID: 31025143     DOI: 10.1007/s00210-019-01655-w

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  29 in total

1.  Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy.

Authors:  M Shikano; H Sobajima; H Yoshikawa; T Toba; H Kushimoto; H Katsumata; M Tomita; S Kawashima
Journal:  Nephron       Date:  2000-05       Impact factor: 2.847

Review 2.  The roles of sodium-glucose cotransporter 2 inhibitors in preventing kidney injury in diabetes.

Authors:  Krit Jaikumkao; Anchalee Pongchaidecha; Varanuj Chatsudthipong; Siriporn C Chattipakorn; Nipon Chattipakorn; Anusorn Lungkaphin
Journal:  Biomed Pharmacother       Date:  2017-07-29       Impact factor: 6.529

3.  Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Authors:  R Kodera; K Shikata; H U Kataoka; T Takatsuka; S Miyamoto; M Sasaki; N Kajitani; S Nishishita; K Sarai; D Hirota; C Sato; D Ogawa; H Makino
Journal:  Diabetologia       Date:  2011-01-21       Impact factor: 10.122

4.  Increased nitric oxide activity compensates for increased oxidative stress to maintain endothelial function in rat aorta in early type 1 diabetes.

Authors:  A Joshi; O L Woodman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-11       Impact factor: 3.000

Review 5.  Nitric oxide in the normal kidney and in patients with diabetic nephropathy.

Authors:  Paolo Tessari
Journal:  J Nephrol       Date:  2014-09-13       Impact factor: 3.902

6.  Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.

Authors:  Biyu Hou; Guifen Qiang; Yuerong Zhao; Xiuying Yang; Xi Chen; Yu Yan; Xiaobo Wang; Chenge Liu; Li Zhang; Guanhua Du
Journal:  Cell Physiol Biochem       Date:  2017-12-18

7.  Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis.

Authors:  In Ah Choi; Sang Jin Lee; Won Park; Sung Hwan Park; Seung-Cheol Shim; Han Joo Baek; Dae-Hyun Yoo; Hyun Ah Kim; Soo Kon Lee; Yun Jong Lee; Young Eun Park; Hoon-Suk Cha; Eun Young Lee; Eun Bong Lee; Yeong Wook Song
Journal:  Arch Rheumatol       Date:  2018-03-23       Impact factor: 1.472

8.  Effect of interleukin 6 deficiency on renal interstitial fibrosis.

Authors:  Jun Yang; Jiyuan Chen; Jingyin Yan; Liping Zhang; Gang Chen; Liqun He; Yanlin Wang
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

Review 9.  Urinary Markers of Tubular Injury in Early Diabetic Nephropathy.

Authors:  Temesgen Fiseha; Zemenu Tamir
Journal:  Int J Nephrol       Date:  2016-05-16

10.  Sitagliptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway.

Authors:  Dongdong Wang; Guanying Zhang; Xiao Chen; Tong Wei; Chenxu Liu; Chun Chen; Yinhan Gong; Qunli Wei
Journal:  Int J Mol Med       Date:  2018-02-16       Impact factor: 4.101

View more
  6 in total

Review 1.  Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.

Authors:  Sandra Rayego-Mateos; José Luis Morgado-Pascual; Lucas Opazo-Ríos; Melania Guerrero-Hue; Cristina García-Caballero; Cristina Vázquez-Carballo; Sebastián Mas; Ana Belén Sanz; Carmen Herencia; Sergio Mezzano; Carmen Gómez-Guerrero; Juan Antonio Moreno; Jesús Egido
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

2.  Calpain-10 drives podocyte apoptosis and renal injury in diabetic nephropathy.

Authors:  Tao Wang; Yanbin Gao; Xiaolei Wang; Yimin Shi; Jiayi Xu; Bingjie Wu; Jiaxin He; Yimeng Li
Journal:  Diabetes Metab Syndr Obes       Date:  2019-09-11       Impact factor: 3.168

3.  Clinical efficacy of linagliptin combined with irbesartan in patients with diabetic nephropathy.

Authors:  Jie Liu; Jing Zhang; Ming-Hui Hou; Wei-Xuan Du
Journal:  Pak J Med Sci       Date:  2022 Jan-Feb       Impact factor: 1.088

Review 4.  A Shared Nephroprotective Mechanism for Renin-Angiotensin-System Inhibitors, Sodium-Glucose Co-Transporter 2 Inhibitors, and Vasopressin Receptor Antagonists: Immunology Meets Hemodynamics.

Authors:  Giovanna Capolongo; Giovambattista Capasso; Davide Viggiano
Journal:  Int J Mol Sci       Date:  2022-04-01       Impact factor: 5.923

5.  Activation of TGR5 Ameliorates Streptozotocin-Induced Cognitive Impairment by Modulating Apoptosis, Neurogenesis, and Neuronal Firing.

Authors:  Ronghao Mu; Xian Wu; Danhua Yuan; Jiajia Zhao; Susu Tang; Hao Hong; Yan Long
Journal:  Oxid Med Cell Longev       Date:  2022-04-15       Impact factor: 7.310

6.  Effects of tocilizumab and dexamethasone on the downregulation of proinflammatory cytokines and upregulation of antioxidants in the lungs in oleic acid-induced ARDS.

Authors:  Funda Terzi; Beste Demirci; İrfan Çınar; Mohammad Alhilal; Huseyin Serkan Erol
Journal:  Respir Res       Date:  2022-09-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.